HDAC9 and glioblastoma: However, the clinical efficacy of the EZH2 inhibitor tazemetostat in GBM remains controversial, and its specific benefits require careful evaluation (112, 113); HDAC inhibitors (HDACIs), on the other hand, hold potential as therapeutic agents by regulating oncogene transcription and cell cycle, among other processes (114).